메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

[ 메디채널 김갑성 기자 ] AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients with heavily pretreated EGFR Wild-type NSCLC and other advanced solid tumors without CD44v9 pre-selection SHANGHAI, Oct. 17, 2025 -- Multitude Therapeutics, Inc., a clinical-stage company focused on the development of antibody-drug-conjugate (ADC) drugs, today announced initial data from its ongoing phase I/II
- 김갑성 기자
- 2025-10-17 22:00
NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension

NEW YORK, Oct. 17, 2025 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension Kristen Scholer delivers the pre-market update on October 17th Stocks are lower early Friday after regional bank reports created concerns over bad loans. Loose lending practices pushed traders into safe havens. Activity in the banking sector could infor
- 황정호 기자
- 2025-10-17 20:55
Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC

CHENGDU, China, Oct. 17, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin (also known as A166) was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (BC) who have received one or more prior anti-HER2 therapy. The approval is based on a multi-center, randomized, open-label
- 김갑성 기자
- 2025-10-17 20:22
One Heung Kong released the White Paper on Global Sustainable and Healthy Living Environments jointly with other institutions

GUANGZHOU, China, Oct. 17, 2025 -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune 500 companies. At the event, the White Paper on Global Sustainable and Healthy Living Environments (the Global Healthy Living Environment Report) was unveiled, setting a fresh yardstick for fostering healthy living across the globe. With the rapid pace of global urbanization, traditional residenti
- 김갑성 기자
- 2025-10-17 18:39
One Heung Kong Leads the Way! New Global Benchmark for Healthy Living Announced

GUANGZHOU, China, Oct. 17, 2025 -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune 500 companies. At the event, the White Paper on Global Sustainable and Healthy Living Environments (the Global Healthy Living Environment Report) was unveiled, setting a fresh yardstick for fostering healthy living across the globe. With the rapid pace of global urbanization, traditional residenti
- 김갑성 기자
- 2025-10-17 18:35
HMI Medical Signs MOA With Ibraco Berhad To Acquire Land For The Establishment Of Its Third Hospital In Malaysia

The new tertiary hospital will be located within the NorthBank Township in Kuching, Sarawak and is targeted to launch in 2029 SINGAPORE, Oct. 17, 2025 -- Health Mangement International Pte Ltd ("HMI Medical") has signed a Memorandum of Agreement ("MoA") with KLSE listed and Sarawak-based property and infrastructure developer, Ibraco Berhad, ("Ibraco") for the acquisition of land for the construction of its third hospital in Malaysia. Fully owned and operated by HMI Medical, Regency Hospital Kuching, a new private specialist hospital will be located
- 김갑성 기자
- 2025-10-17 16:49
Chula Launches Newborn Genome Sequencing Project for Early Detection and Prevention of Genetic Diseases

BANGKOK, Oct. 17, 2025 -- The Center of Excellence in Medical Genetics, Faculty of Medicine, Chulalongkorn University, has launched one of the world's first projects to perform long-read whole genome sequencing in newborns. The initiative screens for 113 genetic diseases, with the goal of early prevention and treatment, opening a new frontier in precision medicine and improving lifelong health outcomes. Genomic Medicine: A New Dimension in Health Care Modern medicine has entered a new era by decoding the genetic foundations of diseases. Genomic medicine can reveal who i
- 김갑성 기자
- 2025-10-17 16:00
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

[ 메디채널 김갑성 기자 ] New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide Intention to pursue a Hong Kong initial public offering (IPO) to expand access to global capital and innovation through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX) Name change to be effective following shareholder approval, which is expected at the Extraordinary General Meeting (EGM) on October 24, 2025 Pending acquisition of AM712 (also know
- 김갑성 기자
- 2025-10-17 15:21
대만 경제부 산업기술국, 대만 이노테크 엑스포에서 첨단 기술 65종 선보여

[ 메디채널 김갑성 기자 ] AI 의류 분류 시스템 및 우울증 치료 신장비 공개 타이베이 2025년 10월 17일 -- 대만 경제부 산하 산업기술국(DoIT)이 오늘 대만 이노테크 엑스포(TIE)의 혁신경제관(Innovation Economy Pavilion)에서 12개 연구기관 및 산업 파트너와 함께 스마트 제조, 탄소중립 지속가능성, 헬스케어 분야를 아우르는 65가지 혁신 기술을 선보인다. 2025 오사카 엑스포의 라이프 시어터(Life Theater)에 적용된 것과 동일한 공업기술연구원(ITRI)의 디지털 트윈 인터랙티브 퍼포밍 기술로 구동되는 높이 3미터의 '테크놀로지 워터폴(technology waterfall)'이 디스플레이와 로봇팔 간의 매끄러운 연동을 뽐내며 첫 선을 보였다. HIWIN, OKOME STUDIO 등 산업 파트너들과 공동 개발한 이 시스템은 스마트 팩토리 수준의 첨단 소프트웨어-하드웨어 통합 기능을 자랑한다. 테크놀로지 워터폴은 500개 이상의 디스플레이와 로봇팔을 동시에 제어하며 20밀리초 이내의 동기화 오차를 유지해 놀라운 정밀도의 하드웨어-소프트웨어 연동 능력을 보여준다.
- 김갑성 기자
- 2025-10-17 14:52
FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications – adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the U.S.[1],[2] Pediatric UV is a rare eye inflammation in children, representing 5–10% of all uveitis cases in the U.S., while HS affects approximately 1–4% of the U.S. population[3],[4] Celltrion strengthens and expands its biosimilars immunology portfolio in the U.S., advancing affordable treatment options for patients living with chronic immune-mediated diseases INCHEON, South K
- 김갑성 기자
- 2025-10-17 13:32

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-10-18_SAT

2025-10-17_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 18일 06시 40분